Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Overview: antifungal combination therapy.

A M Sugar1

  • 1Boston Medical Center, MA 02118, USA. asugar@medicine.bumc.bu.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|March 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antifungal combination therapy: where we stand.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2006
Same author

Fluconazole in transplant recipients: options and limitations.

Transplant infectious disease : an official journal of the Transplantation Society·2001
Same author

Combined treatment: antifungal drugs with antibodies, cytokines or drugs.

Medical mycology·2001
Same author

Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.

Antimicrobial agents and chemotherapy·2001
Same author

Effect of grapefruit juice on serum voriconazole concentrations in the mouse.

Medical mycology·2000
Same author

Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles.

Antimicrobial agents and chemotherapy·2000
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Combination antifungal therapy shows potential but requires careful study. Future research must define drug interactions and optimal experimental designs for treating fungal infections, guiding cautious clinical use.

Area of Science:

  • Mycology
  • Pharmacology
  • Clinical Medicine

Background:

  • The clinical efficacy of combination antifungal therapy remains largely unrealized.
  • Emerging literature highlights both potential benefits and drawbacks of using multiple antifungal agents concurrently.
  • Understanding drug interactions is crucial for optimizing antifungal treatment strategies.

Purpose of the Study:

  • To review the current understanding of combination antifungal therapy.
  • To emphasize the need for rigorous laboratory studies to elucidate drug interactions.
  • To discuss the challenges in designing appropriate experimental models for evaluating combination antifungal efficacy in human mycoses.

Main Methods:

  • Literature review of existing studies on combination antifungal therapy.

Related Experiment Videos

  • Analysis of reported positive and negative aspects of combined drug use.
  • Discussion of experimental design considerations for future research.

    • Main Results:

    • The full clinical benefits of combination antifungal therapy are not yet established.
    • Laboratory studies are essential to define interactions between different antifungal compounds.
    • Appropriate experimental designs are needed to accurately reflect outcomes in treating human fungal infections.

    Conclusions:

    • Combination antifungal therapy requires a cautious, case-by-case approach.
    • Further research is necessary to establish optimal protocols and predict clinical outcomes.
    • Defining the best experimental parameters for studying combination antifungal therapy is a key challenge for the coming years.